Broome Oncology

Myeloproliferative Neoplasms MPN News

Long Term Follow Up Shows Durability of Jakafi® Response in Patients with Polycythemia Vera (December 27, 2017)

CancerConnect News: Jakafi® (ruxolitinib) was initially reported to help patients with polycythemia vera (PV) maintain hematocrit control more effectively than the best available therapy at the 56th American Hematology Society Annual Meeting in 2014.1,2... Continue Reading

Fedratinib May Represent New Option for Jakafi-Resistant Myelofibrosis (December 6, 2017)

Patients with myelofibrosis resistant or intolerant to Jakafi (ruxolitinib) may have an alternative treatment option with a novel JAK2-selective inhibitor fedratinib, according to the results of clinical study recently published in the medical journal... Continue Reading

Incyte Announces Initiation of Clinical Trial Evaluating Jakafi® for the Treatment of Essential Thrombocythemia (November 22, 2017)

Incyte Corporation announced that the first patient has been treated in the RESET pivotal trial evaluating Jakafi®  (ruxolitinib) compared to anagrelide for the treatment of patients with essential thrombocythemia (ET) who are resistant to or intolerant... Continue Reading

5-Year Survival Improved with Early Use of Jakafi® in Myelofibrosis (December 20, 2016)

An analysis of 5-year data from two large clinical trials provide conclusive support that treatment with Jakafi® (ruxolitinib) improves long-term survival, compared to other treatment options for patients with myelofibrosis. Perhaps even more importantly,... Continue Reading

Interferon No Better Than Hydroxyurea and Associated with Worse Side Effects in Polycythemia Vera and Essential Thrombocythemia (December 16, 2016)

The use of interferon as initial therapy in MPN is associated with worsening side effects the longer it is used for treatment. These results were recently presented at the 2016 annual meeting of the American Society of Hematology. Myeloproliferative neoplasms... Continue Reading

Duration of Blood Storage Does Not Affect Outcomes for Patients Requiring Blood Transfusions (December 1, 2016)

The length of time that blood is stored prior to a blood transfusion, within normal ranges, does not appear to affect mortality among patients requiring transfusions. These results were recently published in the New England Journal of Medicine. Many patients... Continue Reading

Myeloproliferative Neoplasms Greatly Affect Patient Quality of Life (October 10, 2016)

According to results from the myeloproliferative neoplasms (MPN) Landmark survey, MPN’s negatively affect the quality of life and overall health of patients even a year before their diagnosis. Myeloproliferative neoplasms (MPN) are a related group of... Continue Reading

Jakafi Superior to Standard Treatment in Polycythemia Vera (June 21, 2016)

Treatment with Jakafi® (ruxolitinib) was superior to best available treatment among patients with inadequately controlled polycythemia vera (PV). These results were recently presented at the 21st Congress of the European Hematology Association (EHA)... Continue Reading

Jakafi Significantly Improves Long-Term Outcomes in Myelofibrosis (June 7, 2016)

The agent Jakafi® (ruxolitinib) has demonstrated significant improvements in long-term outcomes for patients diagnosed with myelofibrosis. These results were recently presented at the 2016 annual meeting of the American Society of Clinical Oncology... Continue Reading

Pacritinib Development in Myelofibrosis Placed on Clinical Hold by the FDA (April 27, 2016)

The investigative agent, pacritinib, being evaluated for treatment of myelofibrosis has been placed on full clinical hold by the United States Food and Drug Administration (FDA). All trials including treatment involving pacritinib have been stopped, and... Continue Reading